title: Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting.
abstract: Trastuzumab has had a major impact on outcomes in HER2-positive breast cancer, but innate or acquired resistance to it is recognized as a problem that can limit its effectiveness. Given its locus of action, the oral tyrosine kinase inhibitor lapatinib would be expected to counteract many of the proposed mechanisms of trastuzumab resistance. It has demonstrated activity in trastuzumab-resistant patients, and neoadjuvant studies in HER2+ patients have demonstrated higher pathologic complete response (pCR) rates with the addition of lapatinib to trastuzumab and chemotherapy. TBCRC006 was a phase II neoadjuvant trial that studied the efficacy of the lapatinib and trastuzumab combination without concurrent chemotherapy, but with estrogen deprivation therapy in ER+ patients. In 65 patients with T2-3 HER2+ cancers, the overall pCR rate was 27%, including 36% in ER-tumors. A total 54% of ER+/HER2+ patients had either a pCR or were downstaged to T <1 cm. Correlative studies on tissue obtained prior to and during neoadjuvant therapy are underway. These results suggest that a significant fraction of HER2+ patients will respond to dual HER2-targeted therapy without cytotoxic chemotherapy, and that antihormonal therapy to block ER/HER2 'crosstalk' may be necessary to achieve optimal responses in ER+/HER2+ patients.
authors.affiliation: Alpert Medical School of Brown University, Providence, Rhode Island, USA.
authors.forename: William M
authors.initials: WM
authors.lastname: Sikov
keywords: HER2-positive breast cancer; lapatinib; neoadjuvant therapy; trastuzumab
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1138-44
references.pmid: 20124182
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4909-19
references.pmid: 17699871
references.citation: Breast Cancer Res. 2011;13(6):R121
references.pmid: 22123186
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4414-22
references.pmid: 17785706
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: Clin Cancer Res. 2010 Aug 15;16(16):4226-35
references.pmid: 20664024
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references.pmid: 19786658
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: J Clin Oncol. 2009 Apr 20;27(12):1999-2006
references.pmid: 19289619
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references.pmid: 20124187
references.citation: Cancer Res. 2008 Jul 15;68(14):5878-87
references.pmid: 18632642
references.citation: J Clin Oncol. 2013 May 10;31(14):1726-31
references.pmid: 23569315
references.citation: Lancet Oncol. 2013 Nov;14(12):1183-92
references.pmid: 24095300
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5529-37
references.pmid: 19786670
references.citation: Lancet Oncol. 2012 Jan;13(1):25-32
references.pmid: 22153890
references.citation: Anticancer Drugs. 2011 Feb;22(2):128-35
references.pmid: 21218604
references.citation: Lancet. 2010 Jan 30;375(9712):377-84
references.pmid: 20113825
references.citation: Lancet. 2012 Feb 18;379(9816):633-40
references.pmid: 22257673